WEKO3
アイテム
{"_buckets": {"deposit": "39474bf1-cb1d-4304-9fbe-739cbf9fa861"}, "_deposit": {"created_by": 2, "id": "14826", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "14826"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00014826", "sets": ["11"]}, "author_link": ["54414", "54415", "54417", "54416", "54413", "54412"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2011", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "10", "bibliographicPageStart": "1", "bibliographicVolumeNumber": "50", "bibliographic_titles": [{"bibliographic_title": "Internal Medicine"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The natural history of the disease varies greatly among individual patients with primary biliary cirrhosis (PBC). Some patients live long without any symptoms while other patients present jaundice and develop hepatic failure in early phases of the disease. Previous studies showed that the natural course of PBC is altered by the use of ursodeoxy cholic acid (UDCA). In this review we discuss variation in the natural course of the disease and it\u0027s alteration by UDCA, and risk factors that predict disease progression. Based on clinical observations, there are three types of clinical evolution in PBC: 1) minimal to slow progression over several years; 2) rapid progression to jaundice and hepatic failure, and 3) progression to portal hypertension without developing deep jaundice. Notably, based on our analyses accelerated progression to jaundice and liver failure are reflected by a sustained serologic presence of anti-gp210 antibodies whereas patients with portal hypertension in the absence of jaundice have anti-centromere autoantibodies. These observations highlight the clinical importance of antinuclear antibody analysis in patients with PBC.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Internal Medicine, 50(1), pp.1-10; 2011", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Japanese Society of Internal Medicine"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.2169/internalmedicine.50.4462", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright (c) 2011 by The Japanese Society of Internal Medicine"}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10827774", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "09182918", "subitem_source_identifier_type": "ISSN"}]}, "item_2_text_62": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "日本内科学会"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ishibashi, Hiromi"}], "nameIdentifiers": [{"nameIdentifier": "54412", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Komori, Atsumasa"}], "nameIdentifiers": [{"nameIdentifier": "54413", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimoda, Shinji"}], "nameIdentifiers": [{"nameIdentifier": "54414", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ambrosini, Yoko M."}], "nameIdentifiers": [{"nameIdentifier": "54415", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Gershwin, M. Eric"}], "nameIdentifiers": [{"nameIdentifier": "54416", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Minoru"}], "nameIdentifiers": [{"nameIdentifier": "54417", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "IntMed50_1.pdf", "filesize": [{"value": "192.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 192400.0, "url": {"label": "IntMed50_1.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/14826/files/IntMed50_1.pdf"}, "version_id": "0d0ed790-4069-4bc3-9943-110a07ab9286"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Autoantibody", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Centromere", "subitem_subject_scheme": "Other"}, {"subitem_subject": "gp210", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Natural history", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Primary biliary cirrhosis", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Prognosis", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Risk Factors and Prediction of Long-term Outcome in Primary Biliary Cirrhosis", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Risk Factors and Prediction of Long-term Outcome in Primary Biliary Cirrhosis"}]}, "item_type_id": "2", "owner": "2", "path": ["11"], "permalink_uri": "http://hdl.handle.net/10069/24829", "pubdate": {"attribute_name": "公開日", "attribute_value": "2011-03-30"}, "publish_date": "2011-03-30", "publish_status": "0", "recid": "14826", "relation": {}, "relation_version_is_last": true, "title": ["Risk Factors and Prediction of Long-term Outcome in Primary Biliary Cirrhosis"], "weko_shared_id": 2}
Risk Factors and Prediction of Long-term Outcome in Primary Biliary Cirrhosis
http://hdl.handle.net/10069/24829
http://hdl.handle.net/10069/248298fb39ada-017a-4085-973a-8c3733e1f5b8
名前 / ファイル | ライセンス | アクション |
---|---|---|
IntMed50_1.pdf (192.4 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2011-03-30 | |||||
タイトル | ||||||
タイトル | Risk Factors and Prediction of Long-term Outcome in Primary Biliary Cirrhosis | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Autoantibody | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Centromere | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | gp210 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Natural history | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Primary biliary cirrhosis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Prognosis | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Ishibashi, Hiromi
× Ishibashi, Hiromi× Komori, Atsumasa× Shimoda, Shinji× Ambrosini, Yoko M.× Gershwin, M. Eric× Nakamura, Minoru |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The natural history of the disease varies greatly among individual patients with primary biliary cirrhosis (PBC). Some patients live long without any symptoms while other patients present jaundice and develop hepatic failure in early phases of the disease. Previous studies showed that the natural course of PBC is altered by the use of ursodeoxy cholic acid (UDCA). In this review we discuss variation in the natural course of the disease and it's alteration by UDCA, and risk factors that predict disease progression. Based on clinical observations, there are three types of clinical evolution in PBC: 1) minimal to slow progression over several years; 2) rapid progression to jaundice and hepatic failure, and 3) progression to portal hypertension without developing deep jaundice. Notably, based on our analyses accelerated progression to jaundice and liver failure are reflected by a sustained serologic presence of anti-gp210 antibodies whereas patients with portal hypertension in the absence of jaundice have anti-centromere autoantibodies. These observations highlight the clinical importance of antinuclear antibody analysis in patients with PBC. | |||||
書誌情報 |
Internal Medicine 巻 50, 号 1, p. 1-10, 発行日 2011 |
|||||
出版者 | ||||||
出版者 | Japanese Society of Internal Medicine | |||||
出版者別言語 | ||||||
日本内科学会 | ||||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 09182918 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA10827774 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.2169/internalmedicine.50.4462 | |||||
権利 | ||||||
権利情報 | Copyright (c) 2011 by The Japanese Society of Internal Medicine | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Internal Medicine, 50(1), pp.1-10; 2011 |